Psyence Biomed Progresses in Psilocybin Development for Alcohol Use Disorder

LOS ANGELES- Psyence Biomed, a biopharmaceutical company focused on psychedelic therapeutics, has provided an update on its development of high-purity psilocybin in collaboration with PsyLabs. The company is working towards producing Active Pharmaceutical Ingredients (APIs) certified under the European Union’s Good Manufacturing Practices (GMP). This certification is critical for advancing psilocybin as a treatment for Alcohol Use Disorder (AUD).

The progress update highlights PsyLabs’ commitment to supplying high-purity, pharmaceutical-grade psilocybin for future clinical trials. Psyence Biomed’s partnership with PsyLabs also includes a pending acquisition of an equity stake, which will further integrate the two companies. This collaboration is expected to streamline the production and distribution of nature-derived psilocybin, facilitating its potential approval by regulatory agencies such as the U.S. FDA​

PsyLabs’ proprietary extraction methods aim to ensure consistent quality and purity, aligning with increasing regulatory scrutiny on psychedelic-based drug development. This progress marks a key step toward developing effective mental health treatments based on psilocybin, particularly for AUD and other substance use disorders​

Both companies remain optimistic about the commercial viability of these developments, with ongoing clinical trials expected to drive further innovation in this emerging sector of mental health treatment.